This provided the first evidence that ERK5 activation might serve as an escape route in order to compensate for MAPKi, allowing tumor cells with an activated RAS/RAF/MEK/ERK pathway to resist the targeted MAPKi therapy. This evidence concerns the gene MAPK7 and neoplasm.